Late Breaking Clinical Data for Prostate Cancer Patients

Session 4: Late Breaking Clinical Data for Prostate Cancer Patients

8:05 AM – 9:20 AM

Moderators:
Howard Soule, PhD
Prostate Cancer Foundation

Introduction
Howard Soule, PhD
Prostate Cancer Foundation

Combinatorial Targeting of AR and AKT with Abiraterone and Ipatasertib for mCRPC with and without PTEN loss: The Ipatential150 Phase 3 Trial
Johann de Bono, MD, PhD
The Institute of Cancer Research; Royal Marsden Hospital, London, UK

Phase 1 Clinical Profile of AMG 160, a Half-Life Extended PSMA Bispecific T-cell Engager (BiTE®) Immunotherapy for Patients with Metastatic Castration-Resistant Prostate Cancer
Matthew Rettig, MD
University of California, Los Angeles; VA Greater Los Angeles Healthcare System

Phase 1 Study of AMG 509, a STEAP1 x CD3 T Cell–Recruiting XmAb® 2+1 Immune Therapy, in Patients with Metastatic Castration-Resistant Prostate Cancer (mCRPC)
Wm. Kevin Kelly, DO
Sidney Kimmel Medical College at Thomas Jefferson University; Sidney Kimmel Cancer Center

Human Costimulatory Bispecific Antibodies in Cancer Immunotherapy: Focus in Prostate Cancer
Dimitris Skokos, PhD
Regeneron Pharmaceuticals

Elizabeth Miller, MD
Regeneron Pharmaceuticals

Live Session Discussion

9:20 AM – 9:25 AM     Please Return to the Virtual Lobby to Join the Next Session